EcoDrugPlus

Phosphodiesterase 4b

Ensembl ID : ENSCHOG00000010469
Gene Symbol: PDE4B
1 Cross references
298 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSCHOG00000000056
Gene Symbol: PDE4D
1 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSCHOG00000010611
Gene Symbol: PDE5A
1 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSCHOG00000006676
Gene Symbol: PDE7A
1 Cross references
240 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSCHOG00000011822
Gene Symbol: PDE7B
1 Cross references
174 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSCHOG00000002238
Gene Symbol: PIK3R1
1 Cross references
259 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSCHOG00000000729
Gene Symbol: PLA2G2A
1 Cross references
173 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSCHOG00000010728
Gene Symbol: PLA2G5
1 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSCHOG00000000172
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSCHOG00000006239
Gene Symbol: PLA2G10
1 Cross references
250 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSCHOG00000007399
Gene Symbol: GART
1 Cross references
247 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSCHOG00000005320
Gene Symbol: PLAT
1 Cross references
203 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).